Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
27-Jan-17
Market
Market
Morning Traded Market
KEY LEVELS
Support 1 : 8429
Support 2 : 8227
Value
% Change
SGX NIFTY
8,667.00
-0.32%
NIKKIE
19456.43
0.28%
HANG SENG
23,347.50
-0.11%
Sensex
Nifty
27,708.00
8,602.75
1.21%
1.50%
DOW
NASDAQ
20,100.91
5,655.18
0.16%
-0.02%
CAC
4,867.24
-0.21%
DAX
11,848.63
0.36%
FTSE
EW ALL SHARE
7,161.49
15,595.89
-0.04%
1.15%
Resistance 2: 8674
Resistance 3: 8736
Market Outlook
Indian equities gave a sharp up move
throughout the day on Wednesday and after
opening on a positive note, Nifty
Event Today continuously rose to make a high of
Quarterly Results
8612.15. At the end of the day the index
AVANTI, COLPAL, BEL
closed the January future and
option
expiry at 8602.75. The broader market was
BINANIIND ,EVEREADY,
INDIACEM , ITC, JUSTDIAL, in the grip of bulls and the midcap and small
indices closed after gaining over 1% each.
KKCL , LGBFORGE ,
On the sectoral front, Banking, Media and
SUNDARMFIN, SHANTIGEAR
Financial services stocks were on the buyers
TATACOFFEE , ZUARI
radar while Pharmaceuticals and IT indices
closed in red. The breadth of the market
Board Meetings
was positive and about three shares
ABGSHIP : General
advanced for two shares declined at NSE.
The Indian Sugar Mills Association (ISMA)
has lowered its sugar production estimate
Concall
by about 9% at 21.3 million tonnes for FY
Chola Invest : 10:00 AM
IDFC Bank : 10:30 AM
2016-17 as against 23.37 lakh tonnes
Ashok Leyland : 10:30 AM projected in September 2016. A drop in
Heritage Foods : 2:30 PM production could lift local prices and prompt
Coromandel Intl : 2:30 PM the world's largest consumer to allow duty
free imports of the sugar.
Karur Vysya Bk : 3:00 PM
Post breaking the resistance of 8444 Nifty
Tata Elxsi : 3:00 PM
made a large trading swing accelerated by
settlement related factors. Going ahead
Raymond : 4:00 PM
budget will be key for shot term trend.
% Change in 1 day
Value
% Change
28385.00
-1.18%
41193.00
-1.26%
53.77
-0.02%
226.80
-0.35%
68.08
0.00%
0.02%
0.08%
72.82
85.86
% Change in 1 day
Institutional Turnover
FII
Investor
Buy(Cr.)
Sale(Cr.)
Net(Cr.)
8874
7495
1379
Jan-17
23976
26854
(2878)
2017
23976
26854
(2878)
Buy(Cr.)
Sale(Cr.)
Net(Cr.)
3576
3193
383
Jan-17
18807
15716
3091
2017
18807
15716
3091
25-Jan-17
DII
Investor
25-Jan-17
Quote of the Day : "Develop into a lifelong self-learner through voracious reading; cultivate curiosity and
strive to become a little wiser every day." Charlie Munger
Narnolia Securities Ltd
IEA Snapshot
BIOCON
NEUTRAL"
Approval from USFDA and EMA for Bio-similar Trastuzumab will help the company to take advantage of this huge opportunity. Apart from
that Biocons management expects growth from Malaysian facility to boost further by expected qualification of this facility by emerging
markets regulators in coming quarters. On the contrary ongoing price control pressure in India and US and discontinuance of key products
may put some uncertainties in near term. Hence we maintain Neutral rating in this stock.
JYOTHYLAB
"BUY"
Going forward, management is confident of demand revival as demonetization effect will ease of. As far as margin is concern, the company
is looking to increase prices by 5-7% going ahead which gives us confidence that company may protect margin going forwards.
Implementation of GST may be game changer for Organized FMCG players. It may boost market share of the company in times to come.
Lastly, JYOTHYLAB gets large chunk of its revenue from South market and South market conditions are improving rapidly which is positive
for this company. Considering better volume growth in Q3FY17, companys guidance for pricing growth, dominance in South market and
expected implementation of GST in FY18, We have positive view on this company with price target of Rs 410.
*For details, refer to our daily report- India Equity Analytics
Top News
Maruti Concall Highlights:
> Other income increased on account of huge capital gains.
>Royalty rate for the quarter stood at 5.5%; if there is no
currency movement then the same rate would be applicable
going ahead.
> Waiting period for Baleno: 24 weeks; Brezza: 18 weeks and
Ignis: 8-10 weeks
> Discounts for the quarter was Rs.19048.
> Commodity prices are going up so some cost pressure would
be in 4QFY17 but bulk of impact has been reflected in 3QFY17
> The company has not taken any price increase.
> Sales from government employees has been robust (sales
contribution 20%)
> Capex plan-Rs.3500 crore; large chunk of it would be for new
models and rest is for R&D expenses and maintenance of old
plants.
> Maintenance capex is approx Rs.700-800 crores but this may
go up going ahead.(machineries are 30 years old)
> Marketing expenses are 2.6% of sales and this would be
slightly higher going ahead.
> Target audinece for Ignis is 18-25 years.
> The company has plans to launch atleast one new model every
year.
Mgt Int : BIOCON
Biocon is well poised to be a frontrunner in biosimilars. The
acceptance of biosimilar Trastuzumab by the USFDA is a huge
milestone for Mylan and Biocon
">>Expects its Malaysian facility, which has begun commercial
operations, to contribute to insulin sales. The order from
Malaysia for insulin is worth USD 75 million over 3 years and is
extendable by another two years.
>>The facility will help Biocon resolve supply challenges it faced
in India
Individual
Foreign Institutions
Nifty Movers
TRADING IDEAS
Scrip
Reco
Initiation Price
Target 1
M&M
Buy
1243.8
1274
BATAINDIA
Feb.450 PE
Short
(1 lot =
1100)
10
1308
Rational
1212
15
Company Name
AAGAMCAP
ADCINDIA
ADVANIHOTR
ANNAINFRA
ARVSMART
AVANTI
BALGOPAL
BEL
BENGALS
BINANIIND
BLIL
COLPAL
COROENGG
DBSTOCKBRO
ELNET
ENVAIREL
EVEREADY
GEOJITBNPP
GGDANDE
GUJALKALI
GUJCOTEX
GUJINTRX
HINAFIL
IMPAL
INDCEMCAP
INDIACEM
INDNIPPON
INDOCO
ITC
JUSTDIAL
KAIRA
KCLINFRA
KIRANSY-B
KIRLOSBROS
KKCL
KWALITYCL
LGBFORGE
LINAKS
MNIL
NEELKAN
NEXTGENT
OPTIFIN
ORVENPR
PASARI
RAJGLOWIR
Date
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
BSE Code
505807
512115
519413
532841
522034
500389
532872
507753
506003
590071
532790
532301
522142
513428
530401
532893
532016
511038
534742
505036
537292
533758
531310
500069
530495
531210
531472
526783
500128
538881
532482
526899
507438
500220
532686
532967
539686
500510
530011
514418
531221
540254
537291
530365
514460
Company Name
ROLCOEN
ROSEMER
RUIAAQA
SAHYADRI
SHANTIGEAR
SILVERLINE
SPARC
SREERAYA
SUDAI
SUNDARMFIN
TANLA
TATACOFFEE
TECHFOR
TRINETRA
VINYOFL
VTMLTD
WELLESLEY
ZARCOLEA
ZUARI
ACGL
AGRITECH
APLAPOLLO
AVAILFC
BNKCAP
CHHATTIND
COLINZ
CYBELEIND
DRAGARWQ
ELECTCAST
GALADAFIN
GRANULES
HIMIN
IFBAGRO
JASCH
KERNEX
KIRIINDUS
KPEL
LT
MANGCHEFER
MANORG
MAYURFL
MTPL
NATHBIOGEN
ORIENTBELL
OSWAYRN
Date
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
27-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
539354
526490
531688
515127
532972
523236
503811
519242
500404
POLYSPIN
PRATIK
PRITHVISOF
RAMMA
SANKHYAIN
SHRENUJ
SIYSIL
SRDAPRT
SUNFLAG
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
526576
539871
500412
524717
530045
502281
532402
505232
531950
TECHIN
THYROCARE
TIRUMALCHM
TITANBIO
TITANSEC
TRIVENIGQ
USGTECH
VELJAN
VERTEX
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
28-Jan-17
PAT
48
142
2582
39
322
1100
22
PAT Growth ( % )
780.80
3.50
-2.70
43.20
8.90
6.30
-18.30
PAT
86.56
2.77
75.62
185.57
9.33
12.66
163.38
111.81
-14.04
154.12
-7.34
6.11
28.07
70.90
1744.00
17.20
4.15
-14.09
-0.53
1.10
-10.80
100.80
43.78
-24.46
459.18
2109.00
PAT Growth ( % )
-67.88
-810.26
-26.80
-6.58
44.43
57.66
10.37
39.14
-608.70
15.06
-109.12
-16.87
29.00
33.82
71.10
1.06
-7.78
-136.05
-116.99
-66.57
-266.92
157.93
9.72
14.09
60.14
-5.60
Company Name
INDIACEM
COLPAL
ITC
GRANULES
BEL
LT
JUSTDIAL
SALES
1192
995
8810
407
1850
27300
171
BSE Code
533573
513729
500101
500477
532888
500067
511243
506395
508906
500086
532832
500214
533293
532889
532500
532440
512626
500330
502090
532163
502180
509930
500408
505854
512070
507685
Company Name
APLLTD
AROGRANITE
ARVIND
ASHOKLEY
ASIANTILES
BLUESTARCO
CHOLAFIN
COROMANDEL
EVERESTIND
EXIDEIND
IBREALEST
IONEXCHANG
KIRLOSENG
KPRMILL
MARUTI
MPSLTD
ORBTEXP
RAYMOND
SAGCEM
SAREGAMA
SHREDIGCEM
SUPREMEIND
TATAELXSI
TRF
UPL
WIPRO
SALES
777.00
51.43
2335.00
4723.33
245.66
926.00
1184.16
2270.00
251.24
1949.00
300.00
192.00
689.00
613.96
19173.10
80.01
28.12
1306.93
220.50
54.23
63.15
1107.24
309.00
231.22
3987.00
13764.50
sales Growth ( % )
28.20
7.50
-4.00
18.00
21.90
5.70
0.00
Result Q3FY17
Sales Growth ( % )
-15.89
13.48
8.56
17.22
4.92
30.71
12.29
-17.05
-9.91
28.13
-54.45
-5.04
15.80
-0.90
29.83
15.99
-1.33
-5.57
95.25
0.76
-27.49
-20.00
12.74
2.86
18.06
6.28
Country
US
UK/EURO ZONE
Monday
23th Jan 17
Economic Calendar
Tuesday
Wednesday
24th Jan 17
25th Jan 17
INDIA
Thursday
26th Jan 17
Friday
27th Jan 17
Spanish Unemployment
Rate, German Prelim CPI
m/m , Prelim GDP q/q, BBA
Mortgage Approvals, Index
of Services 3m/3m.
Risk Disclosure & Disclaimer: This report/message is for the personal information of
the authorized recipient and does not construe to be any investment, legal or taxation
advice to you. Narnolia Securities Ltd. (Hereinafter referred as NSL) is not soliciting any
action based upon it. This report/message is not for public distribution and has been
furnished to you solely for your information and should not be reproduced or
redistributed to any other person in any from. The report/message is based upon publicly
available information, findings of our research wing East wind & information that we
consider reliable, but we do not represent that it is accurate or complete and we do not
provide any express or implied warranty of any kind, and also these are subject to change
without notice. The recipients of this report should rely on their own investigations,
should use their own judgment for taking any investment decisions keeping in mind that
past performance is not necessarily a guide to future performance & that the the value of
any investment or income are subject to market and other risks. Further it will be safe to
assume that NSL and /or its Group or associate Companies, their Directors, affiliates
and/or employees may have interests/ positions, financial or otherwise, individually or
otherwise in the recommended/mentioned securities/mutual funds/ model funds and
other investment products which may be added or disposed including & other mentioned
in this report/message.